Microarray technology in the study of obesity and non-alcoholic fatty liver disease

被引:14
|
作者
Baranova, A
Schlauch, K
Gowder, S
Collantes, R
Chandhoke, V
Younossi, ZM
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA 22042 USA
[2] George Mason Univ, Ctr Study Genom Liver Dis, Mol & Microbiol Dept, Fairfax, VA 22030 USA
关键词
gene expression; microarray; NAFLD; obesity;
D O I
10.1111/j.1478-3231.2005.01183.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The recent development of high-throughput gene expression technology permits simultaneous investigation of thousands of genes, providing a snapshot of the transcription state of diseased tissue. Microarray-based expression profiling is well suited to investigate the molecular basis of complex diseases such as obesity and chronic liver disease. With the help of microarray technology, functional genomics will surely advance our understanding of these diseases, and lead to more effective, targeted interventions that lack the toxicity of many conventional treatments. Despite their tremendous potential, microarray studies are subject to potential flaws in experimental design, experimental techniques, data analysis, and data interpretation. Besides the technical issues, the most important challenge is to develop integrative databases that combine gene expression data with the clinical data. Over the next few years, advances in technology and refinements in study design and data analysis will make clinically relevant translational research even more engaging and productive.
引用
收藏
页码:1091 / 1096
页数:6
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [32] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [33] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [34] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [35] Current Solutions for Obesity-Related Liver Disorders: Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Raziel, Asnat
    Sakran, Nasser
    Szold, Amir
    Goitein, David
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2015, 17 (04): : 234 - 238
  • [36] The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
    Andreasen, Christine R.
    Andersen, Andreas
    Vilsboll, Tina
    DIABETOLOGIA, 2023, 66 (10) : 1846 - 1858
  • [37] Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease
    Yang, Yao-Jong
    Ni, Yen-Hsuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 : S55 - S61
  • [38] Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease
    Mimi Zhou
    Nan Yang
    Xin Xing
    Danyan Chang
    Juan Li
    Jiang Deng
    Yi Chen
    Chunhua Hu
    Rou Zhang
    Xiaolan Lu
    Yingren Zhao
    Yingli He
    BMC Gastroenterology, 21
  • [39] The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
    Christine R. Andreasen
    Andreas Andersen
    Tina Vilsbøll
    Diabetologia, 2023, 66 : 1846 - 1858
  • [40] Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
    Younossi, ZM
    McCullough, AJ
    Ong, JP
    Barnes, DS
    Post, A
    Tavill, A
    Bringman, D
    Martin, LM
    Assmann, J
    Gramlich, T
    Mullen, KD
    O'Shea, R
    Carey, WD
    Ferguson, R
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (08) : 705 - 709